Patients

Because everyone deserves to live a full life.

We’re fiercely passionate in our belief that declining brain function is something that can be slowed or reversed. That’s why we are working tirelessly so that people living with or at risk for neurodegenerative diseases have a more hopeful future.

Room with natural lighting Caregiver and patient

Frontotemporal Dementia (FTD)

Frontotemporal dementia (FTD) is the most common dementia in individuals under 60. FTD affects roughly 50,000 to 60,000 individuals in the United States and roughly 110,000 individuals in the United Kingdom and European Union. We are searching for genetic treatments that target the dysfunctional brain immune system to slow the progression of FTD.

Alzheimer’s Disease

Alzheimer’s disease is an irreversible degenerative brain disease and the most common form of dementia. It slowly destroys memory and thinking skills, and eventually the ability to carry out the simplest tasks. We are approaching the treatment of Alzheimer’s disease and other neurodegenerative diseases in an entirely new way: by restoring the function of the brain’s innate immune system to maintain neurological function with the hope of one day halting, or possibly even reversing, the course of disease.

Older male with cane older male with cane
patients blade4 als left patients blade4 als right

Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s Disease or Motor Neuron Disease, is a rare neurodegenerative disease that affects up to 30,000 individuals in the United States and approximately 50,000 people in Europe. Mutations within multiple genes, including the C9orf72 gene, are believed to cause the disease.

Expanded Access Policy

Alector is committed to developing safe and effective therapies to transform the lives of patients with neurodegenerative diseases.

image of An older patient and their caregiver Image of smiling caregiver

What’s Next

Our Science

Going where others haven’t.

Leadership

Our team has years of experience in biotechnology and pharmaceutical industries, plus a shared passion to change the course of neurodegenerative diseases.

Our History

We've accomplished a lot in a relatively short time.

Close